Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats

Circulation: Heart Failure

Volumn 5, Issue 6, 2012, Pages 794-802

  Yamazaki, Takanori ^a   Izumi, Yasukatsu ^a,b   Nakamura, Yasuhiro ^a   Yamashita, Naoto ^a   Fujiki, Hiroyuki ^b,c   Osada Oka, Mayuko ^a   Shiota, Masayuki ^a   Hanatani, Akihisa ^a   Shimada, Kenei ^a   Iwao, Hiroshi ^a   Yoshiyama, Minoru ^a  

^a Department of Internal Medicine and Cardiology ^*  (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Arginine vasopressin; Diuretic; Echocardiography; Left ventricular dysfunction; Tolvaptan

Indexed keywords

FUROSEMIDE; TOLVAPTAN; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL INFILTRATION; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FUROSEMIDE; HEMODYNAMICS; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84873670177     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.968750     Document Type: Article

References (37)

1. Gring CN, Francis GS. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol. 2004;44:1841-1846.
2. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br J Pharmacol. 2010;160:1273-1292.
3. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-677.
4. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
5. Costello-Boerrigter LC, Boerrigter G, Cataliotti A, Harty GJ, Burnett JC Jr. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure. Circ Heart Fail. 2010;3:412-419.
6. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860-867.
7. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785-1791.
8. Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF Jr. Vasopressin: A new target for the treatment of heart failure. Am Heart J. 2003;146:9-18.
9. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev. 2009;14:75-82.
10. Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49:2151-2159.
11. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332-1343.
12. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.
13. Pang PS, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JE, Zimmer C, Teerlink JR, Maggioni AP, Burnett JC Jr, Grinfeld L, Ouyang J, Udelson JE, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009;30:2233-2240.
14. Nakamura Y, Yoshiyama M, Omura T, Yoshida K, Izumi Y, Takeuchi K, Kim S, Iwao H, Yoshikawa J. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res. 2003;57:48-54.
15. Yamazaki T, Izumi Y, Nakamura Y, Hanatani A, Shimada K, Muro T, Shiota M, Iwao H, Yoshiyama M. Novel device that produces carbon dioxide mist for myocardial infarction treatment in rats. Circ J. 2012;76:1203-1212.
16. Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H. Anti-edematous effects of tolvaptan in experimental rodent models. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S77-S82.
17. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540-1545.
18. Prunier F, Gaertner R, Louedec L, Michel JB, Mercadier JJ, Escoubet B. Doppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats. Am J Physiol Heart Circ Physiol. 2002;283:H346-H352.
19. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
20. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553.
21. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, Hashimoto K, Yamamoto M, Fujio H, Miura A, Ohta K, Morita H, Saito H, Emori T, Nakamura Y, Kusano I, Ohe T. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J. 2004;68:671-676.
22. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950-1959.
23. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, Wen J, Egashira K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108:2134-2140.
24. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881-889.
25. Jackson BM, Gorman JH, Moainie SL, Guy TS, Narula N, Narula J, John-Sutton MG, Edmunds LH Jr, Gorman RC. Extension of borderzone myocardium in postinfarction dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:1160-7; discussion 1168.
26. Kohno T, Anzai T, Naito K, Sugano Y, Maekawa Y, Takahashi T, Yoshikawa T, Ogawa S. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J. 2008;72:1685-1692.
27. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K, Kudo H, Sugi Y, Fukui D, Yasukawa H, Kuwahara F, Imaizumi T. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res. 2006;29:711-718.
28. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996;271:17779-17784.
29. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
30. Zhuo JL. Monocyte chemoattractant protein-1: A key mediator of angiotensin II-induced target organ damage in hypertensive heart disease? J Hypertens. 2004;22:451-454.
31. Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-1266.
32. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens. 1999;17:537-545.
33. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288-294.
34. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S67-S76.
35. Li X, Chan TO, Myers V, Chowdhury I, Zhang XQ, Song J, Zhang J, Andrel J, Funakoshi H, Robbins J, Koch WJ, Hyslop T, Cheung JY, Feldman AM. Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gaq-mediated cell signaling. Circulation. 2011;124:572-581.
36. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: Role of V1- and V2-vasopressinergic receptors. Am J Physiol. 1988;255(2 Pt 2):H261-H265.
37. Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, Fujiki H, Miyazaki S. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012;5:484-492.